Menu
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.
52 Discovery
Irvine, California 92618-3105
Phone: 19492977000
www.masimo.com
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide
Masimo (NASDAQ: MASI) today announced the publication of a peer-reviewed study regarding Masimo SET pulse oximetry performance in varying skin pigmentation in the Journal of Clinical Monitoring and Computing. The retrospective trial, “Racial effects on Masimo pulse oximetry: a laboratory study,” by Drs. Steven J. Barker and Wilson C. Wilson, found that there was no clinically significant difference
In Thursday’s session, Masimo Corporation (NASDAQ:MASI) marked $137.02 per share, up from $132.45 in the previous session. While Masimo Corporation has overperformed by 3.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MASI fell by -54.36%, with highs and lows ranging from $305.21 to $108.89, whereas […]
The CEO of medical device company Masimo bought roughly $5 million of stock over the past week.
The Neonatal Care Equipment report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows
IRVINE, Calif.--(BUSINESS WIRE)--A federal court has ruled that a former Masimo engineer misappropriated trade secrets related to Masimo’s pulse oximetry technology.
Although US stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Masimo The Trade: Masimo Corporation (NASDAQ: MASI ) … Full story available on Benzinga.com
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:50 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industr
An investigation on behalf of investors in Masimo Corporation (NASDAQ:MASI) shares over potential wrongdoing at Masimo Corporation was announced. San Diego, CA -- ( SBWIRE ) -- 11/09/2022 -- Certain directors of Masimo Corporation are under investigation concerning potential breaches of fiduciary duties. Investors who purchased shares of Masimo Corporation (NASDAQ: MASI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Masimo directors breached their fiduciary duties and caused damage to the company and its shareholders. Irvine CA based Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. Masimo Corporation reported that its annual Total Revenue rose from over $1.14 billion in 2020 to over $1.23 billion in 2021, and that its Net Income declined from $240.3 million in 2020 to $229.64 million in 2021.
The following slide deck was published by Masimo Corporation in conjunction with their 2022 Q3 earnings call.
Masimo Corporation (NASDAQ:NASDAQ:MASI) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Eli Kammerman – Vice President-Business Development and Investor…
Masimo press release (MASI): Q3 Non-GAAP EPS of $1.00 beats by $0.08.Revenue of $549.3M (+78.7% Y/Y) beats by $15.86M.Healthcare revenue was $327 million, representing 6%…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the third quarter of 2022, ended October 1, 2022. Third Quarter 2022 Financial Results Consolidated revenue was $549.3 million, representing 78.7% reported growth compared to $307.4 million in the third quarter of 2021. Healthcare revenue was $327.2 million, which represents 6.4% reported growth and 10.0% growth on a constant currency basis. Non-healthcare revenue was $222.1 million. Excluding handh
Politan Capital filed a complaint against medical-sensor maker Masimo. Bow Street disclosed a large stake in real estate investment trust Veris Residential.
Masimo (NASDAQ: MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, Nove
An investigation for investors in Masimo Corporation (NASDAQ:MASI) shares over potential securities laws violations by Masimo Corporation was announced. San Diego, CA -- ( SBWIRE ) -- 10/25/2022 -- An investigation was announced concerning possible violations of securities laws by Masimo Corporation in connection with certain financial statements. Investors who purchased shares of Masimo Corporation (NASDAQ: MASI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Masimo Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made. Irvine CA based Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. Masimo Corporation reported that its annual Total Revenue rose from over $1.14 billion in 2020 to over $1.23 billion in 2021, and that its Net Income declined from $240.3 million in 2020 to $229.64 million in 2021.
Masimo Corp. (MASI) filed a counterclaim against Politan Capital after the activist sued the medical monitoring company on Friday. "Politan is refusing to provide information about…
A Masimo Corp. (MASI) activist investor has filed a lawsuit in Delaware after the medical monitoring company added some new bylaws that the activist alleges is trying to thwart…
NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.8% stockholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), filed a lawsuit in the Court of Chancery of the State of Delaware today against the Company and its Board of Directors (the “Board”). The suit is in response to amendments to Masimo’s bylaws that the Company adopted on September 9, 2022 (the “Bylaw Amendments”) – one week after its only meeting with Politan – at wh
A lawsuit filed by Apple yesterday accuses medical tech company Masimo of creating an Apple Watch clone, in the form of the W1 Advanced Health Tracking Watch. Masimo rejects the claim, and says that Apple is merely retaliating for its own lawsuit alleging patent infringements by the Cupertino company … Background The battle between the […] The post Apple Watch clone made by Masimo, says Apple lawsuit appeared first on TECHTELEGRAPH .
A lawsuit filed by Apple yesterday accuses medical tech company Masimo of creating an Apple Watch clone, in the form of the W1 Advanced Health Tracking Watch. Masimo rejects the claim, and says that Apple is merely retaliating for its own lawsuit alleging patent infringements by the Cupertino company … Background The battle between the […]
The market was taken by surprise on Masimo''s announcement to acquire Sound United. Read more to know why we rate MASI a BUY.
